DCPH - Deciphera Pharmaceuticals Inc. (DCPH) Q4 2023 Earnings Call Transcript
2024-02-06 16:00:07 ET
Deciphera Pharmaceuticals, Inc. (DCPH)
Q4 2023 Earnings Conference Call
February 06, 2024, 08:00 AM ET
Company Participants
Jen Larson - SVP, Finance and IR
Steve Hoerter - President and CEO
Matt Sherman - Chief Medical Officer
Dan Martin - Chief Commercial Officer
Margarida Duarte - Head, International
Tucker Kelly - CFO
Conference Call Participants
Jessica Fye - JPMorgan
Tyler Van Buren - TD Cowen
Eun Yang - Jefferies
Michael Schmidt - Guggenheim Securities
Christopher Raymond - Piper Sandler
Brad Canino - Stifel
Reni Benjamin - Citizens JMP
Peter Lawson - Barclays
Presentation
Operator
Good morning, everyone, and welcome to Deciphera Pharmaceuticals Fourth Quarter and Full Year 2023 Financial Results Conference Call. Today's call is being recorded.
At this time, I would like to turn the call over to Jen Larson, Senior Vice President of Finance and Investor Relations. Jen?
Jen Larson
Thank you, operator. Welcome and thank you for joining us today to discuss Deciphera's fourth quarter and full year 2023 financial results. I'm Jen Larson, Senior Vice President of Finance and Investor Relations. With me this morning to discuss the financial results and provide a general corporate update are Steve Hoerter, President and Chief Executive Officer; Matt Sherman, Chief Medical Officer; Dan Martin, Chief Commercial Officer; Margarida Duarte, Head of International; and Tucker Kelly, Chief Financial Officer.
Before we begin, I would like to remind you that any statements we make on this call that are not historical facts are forward-looking statements made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Examples include our expectations for our preclinical and clinical programs, our commercialization of QINLOCK, and guidance. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we cannot assure you that our expectations will be achieved. Such risks and uncertainties include those set forth in our most recent annual report on Form 10-K as well as our other SEC filings. We assume no obligation to update or revise any forward-looking statements.
Following this call, a replay will be available on the company's website, www.deciphera.com.
With that, I will now turn the call over to Steve Hoerter, President and Chief Executive Officer of Deciphera. Steve?...
Deciphera Pharmaceuticals, Inc. (DCPH) Q4 2023 Earnings Call Transcript